Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Loh KC, Baldwin D, Saba JD.

Anticancer Agents Med Chem. 2011 Nov;11(9):782-93. Review.

PMID:
21707493
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.

Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A, Ogretmen B.

Future Oncol. 2010 Oct;6(10):1603-24. doi: 10.2217/fon.10.116. Review.

PMID:
21062159
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cancer treatment strategies targeting sphingolipid metabolism.

Oskouian B, Saba JD.

Adv Exp Med Biol. 2010;688:185-205. Review.

PMID:
20919655
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Regulation of sphingosine kinase in hematological malignancies and other cancers.

Pitson SM, Powell JA, Bonder CS.

Anticancer Agents Med Chem. 2011 Nov;11(9):799-809. Review.

PMID:
21707491
[PubMed - indexed for MEDLINE]
5.

Therapeutic applications of bioactive sphingolipids in hematological malignancies.

Ekiz HA, Baran Y.

Int J Cancer. 2010 Oct 1;127(7):1497-506. doi: 10.1002/ijc.25478. Review.

PMID:
20503271
[PubMed - indexed for MEDLINE]
6.

Novel agents targeting bioactive sphingolipids for the treatment of cancer.

Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y.

Curr Med Chem. 2013;20(1):108-22. Review.

PMID:
23244584
[PubMed - indexed for MEDLINE]
7.

Regulation of autophagy by sphingolipids.

Bedia C, Levade T, Codogno P.

Anticancer Agents Med Chem. 2011 Nov;11(9):844-53. Review.

PMID:
21707487
[PubMed - indexed for MEDLINE]
8.

Sphingolipids in cancer.

Furuya H, Shimizu Y, Kawamori T.

Cancer Metastasis Rev. 2011 Dec;30(3-4):567-76. doi: 10.1007/s10555-011-9304-1. Review.

PMID:
22005951
[PubMed - indexed for MEDLINE]
9.

Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.

Kawabori M, Kacimi R, Karliner JS, Yenari MA.

World J Cardiol. 2013 Apr 26;5(4):75-86. doi: 10.4330/wjc.v5.i4.75.

PMID:
23675553
[PubMed]
Free PMC Article
10.

Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.

Gatt S, Dagan A.

Chem Phys Lipids. 2012 May;165(4):462-74. doi: 10.1016/j.chemphyslip.2012.02.006. Epub 2012 Feb 23. Review.

PMID:
22387097
[PubMed - indexed for MEDLINE]
11.

Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.

Selvam SP, Ogretmen B.

Handb Exp Pharmacol. 2013;(216):3-27. doi: 10.1007/978-3-7091-1511-4_1. Review.

PMID:
23563649
[PubMed - indexed for MEDLINE]
12.

Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].

Loughran TP, Wang HG.

Anticancer Agents Med Chem. 2011 Nov;11(9):780-1. No abstract available.

PMID:
22023044
[PubMed - indexed for MEDLINE]
13.

Roles of bioactive sphingolipids in cancer biology and therapeutics.

Saddoughi SA, Song P, Ogretmen B.

Subcell Biochem. 2008;49:413-40. doi: 10.1007/978-1-4020-8831-5_16. Review.

PMID:
18751921
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Principles of bioactive lipid signalling: lessons from sphingolipids.

Hannun YA, Obeid LM.

Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50. doi: 10.1038/nrm2329. Review.

PMID:
18216770
[PubMed - indexed for MEDLINE]
15.

Re-configuration of sphingolipid metabolism by oncogenic transformation.

Don AS, Lim XY, Couttas TA.

Biomolecules. 2014 Mar 14;4(1):315-53. doi: 10.3390/biom4010315.

PMID:
24970218
[PubMed - in process]
Free PMC Article
16.

The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function.

Jessup CF, Bonder CS, Pitson SM, Coates PT.

Endocr Metab Immune Disord Drug Targets. 2011 Dec;11(4):262-72. Review.

PMID:
21696364
[PubMed - indexed for MEDLINE]
17.

Sphingolipid metabolism and drug resistance in hematological malignancies.

Gouaze-Andersson V, Cabot MC.

Anticancer Agents Med Chem. 2011 Nov;11(9):891-903. Review.

PMID:
21707483
[PubMed - indexed for MEDLINE]
18.

Sphingolipid metabolism and leukemia: a potential for novel therapeutic approaches.

Burns TA, Luberto C.

Anticancer Agents Med Chem. 2011 Nov;11(9):863-81. Review.

PMID:
21707485
[PubMed - indexed for MEDLINE]
19.

Sphingolipid regulation of ezrin, radixin, and moesin proteins family: implications for cell dynamics.

Adada M, Canals D, Hannun YA, Obeid LM.

Biochim Biophys Acta. 2014 May;1841(5):727-37. doi: 10.1016/j.bbalip.2013.07.002. Epub 2013 Jul 12. Review.

PMID:
23850862
[PubMed - indexed for MEDLINE]
20.

Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate.

Kihara A, Mitsutake S, Mizutani Y, Igarashi Y.

Prog Lipid Res. 2007 Mar;46(2):126-44. Epub 2007 Mar 14. Review.

PMID:
17449104
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk